Recent 8-K filings for NRC

• April 28, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  NRC Health Q1 revenue up 4% to $34.8M; TRCV record $152.1M (+13% YoY)

  GAAP net income $3.2M ($0.14 diluted EPS); adjusted net income $4.6M ($0.21 adjusted diluted EPS).

• April 28, 2026, 7:59 PM ET other material materiality 0.75 neutral item 5.02

  NRC Health amends exec stock awards, eliminates repurchase right; expects $9.4M Q2 expense

  Committee amended grants to CEO Trent Green (500k shares), COO Helen Hrdy (100k), and Chief Corp Dev Officer Andrew Monich (100k) to eliminate repurchase right.

• April 20, 2026, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.03item 9.01 ◈ Governance Changes ×2

  NRC Health declassifies board, formalizes name change; CFO restricted stock amended

  Name changed to NRC Health from National Research Corp; 'NRC' ticker unchanged; no shareholder vote required.

• March 5, 2026, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  NRC Health TRCV reaches all-time high of $152M, up 13% YoY

  TRCV surpassed $152 million as of March 4, 2026, a new all-time high for NRC Health.

• February 3, 2026, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  NRC Health Q4 2025 revenue $35.2M; TRCV up 8% YoY to $144.1M

  Q4 GAAP net income $1.8M ($0.08 diluted EPS); adjusted net income $3.4M ($0.16 diluted EPS).

• October 27, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  NRC Health Q3 2025: TRCV up 8% to $141.7M; Adj EBITDA +11% YoY to $10.9M

  Revenue $34.6M (+2% QoQ); GAAP net income $4.1M (12% of revenue); Adj net income $5.0M (14% of revenue).

• August 28, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01

  NRC Health names Shane Harrison CFO effective Sept 25, 2025

  Shane Harrison appointed Executive VP and CFO, succeeding Michael D. Hays as principal financial officer.

• July 28, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  NRC Health Q2 2025: TRCV grows 2% sequentially; net margin 0% on exec comp; adj EBITDA margin 30%

  TRCV grew 2% sequentially, third consecutive quarter of growth and highest since Q1 2021.

• May 12, 2025, 7:59 PM ET other materiality 0.40 neutral item 5.02item 5.07

  National Research shareholders approve 2025 Omnibus Incentive Plan, elect directors

  Donald M. Berwick and Stephen H. Lockhart elected as directors for three-year terms.

• April 28, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  National Research Corporation Reports Q1 2025 Results and Announces Share Repurchase Program

  Total recurring value contract value increased sequentially for second consecutive quarter.

• April 22, 2025, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change ×2

  National Research designates CEO Hays as interim PFO, appoints Freeman as CAO

  CEO Michael D. Hays designated principal financial officer; will serve as PEO and PFO until Trent Green becomes CEO on June 1, 2025.

• April 9, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

  NRC adjusts exec compensation ahead of CEO transition; COO gets 100k share grant

  Trent Green to become CEO and director effective June 1, 2025, as previously announced.

• March 4, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 5.02item 9.01 ◈ executive_change ×3

  NRC appoints Trent Green as CEO effective June 1, 2025; Hays becomes Chairman

  Trent Green named CEO effective June 1, 2025; current CEO Mike Hays transitions to Chairman.

• February 10, 2025, 6:59 PM ET debt materiality 0.55 neutral item 1.01item 2.03item 9.01

  National Research enters $140M credit facility ($30M revolver + $110M term loan); $62.4M drawn at closing

  New credit agreement dated Feb 6, 2025 amends and restates 2020 facility with First National Bank of Omaha.

• January 27, 2025, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 7.01item 9.01

  NRC Q4 revenue $36.9M, EPS $0.28; CTO Louvion resigns

  Q4 revenue $36.9M vs $38.0M YoY; diluted EPS $0.28 vs $0.36.

• November 14, 2024, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change

  National Research CFO/PAO Linda Stacy to retire effective Dec 31, 2024

  Linda Stacy notified company of retirement as Secretary, Principal Financial Officer, and Principal Accounting Officer.

• October 25, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  NRC Health Q3 revenue falls 5.5% to $35.8M; EPS drops to $0.24 from $0.32

  Revenue $35.8M vs $37.9M a year ago; diluted EPS $0.24 vs $0.32.

• October 15, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

  National Research appoints Helen L. Hrdy as COO effective Oct 14, 2024

  Helen L. Hrdy, 60, appointed Chief Operating Officer on October 14, 2024.

• August 6, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 1.01item 2.02item 9.01

  NRC Health Q2 revenue $35M, EPS $0.26; amends credit; acquires NOBL Health

  Q2 revenue ~$35M vs ~$36M YoY; diluted EPS $0.26 vs $0.29 YoY; TRCV $138M at June 30.

• May 13, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  NRC shareholders elect directors, ratify KPMG, approve say-on-pay at annual meeting

  Michael D. Hays re-elected with 97.1% of votes cast; John N. Nunnelly with 91.2%.

• May 7, 2024, 7:59 PM ET earnings materiality 0.40 neutral item 2.02item 5.02item 9.01 ◈ executive_change

  NRC Health appoints Linda Stacy as PFO; Q1 dividend $0.12; $40M net debt; no GAAP results disclosed

  Linda Stacy appointed Principal Financial Officer effective May 7, 2024; retains roles as PAAO and Secretary.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event earnings

4 positive 2 negative 15 neutral

source · NRC on sec.gov